iSpecimen Gestione

Gestione criteri di controllo 0/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Amministratore delegato

n/a

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	no data
Proprietà del CEO	n/a
Durata media del management	less than a year
Durata media del Consiglio di amministrazione	less than a year

Aggiornamenti recenti sulla gestione

Recent updates

iSpecimen Inc. (NASDAQ:ISPC) Might Not Be As Mispriced As It Looks After Plunging 32%

Sep 13

US$3.00: That's What Analysts Think iSpecimen Inc. (NASDAQ:ISPC) Is Worth After Its Latest Results

Aug 09

Take Care Before Diving Into The Deep End On iSpecimen Inc. (NASDAQ:ISPC)

Jan 04

Downgrade: Here's How This Analyst Sees iSpecimen Inc. (NASDAQ:ISPC) Performing In The Near Term

Aug 07

Investors Still Aren't Entirely Convinced By iSpecimen Inc.'s (NASDAQ:ISPC) Revenues Despite 33% Price Jump

Apr 18

iSpecimen Inc.'s (NASDAQ:ISPC) Intrinsic Value Is Potentially 69% Above Its Share Price

Mar 31

iSpecimen: High Growth Marketplace At A Discount

Jul 07

iSpecimen raises $18M via Nasdaq IPO

Jun 21

AMMINISTRATORE DELEGATO

iSpecimen non ha un CEO, o non abbiamo dati su di loro.

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Leslie Hoyt	Senior Vice President of Operations	no data	Nessun dato	Nessun dato
Carly Lejnieks	Vice President of Marketing	no data	Nessun dato	Nessun dato
Annette Arnold	Vice President of Sales & Business Development	1.8yrs	Nessun dato	Nessun dato
Evan Cox	Senior Vice President of Strategy & Innovation	less than a year	Nessun dato	Nessun dato
Brielan Smiechowski	Senior Vice President of Business Development	less than a year	Nessun dato	Nessun dato

0.8yrs

Durata media

Gestione esperta: Il team dirigenziale di ISPC non è considerato esperto (durata media 0.8 anni), il che suggerisce un nuovo team.

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
John Brooks	Independent Director	3.4yrs	US$34.93k	0.025% $ 1.1k
Avtar Dhaliwal	Independent Director	less than a year	Nessun dato	Nessun dato
Richard Paolone	Director	less than a year	Nessun dato	Nessun dato
Katharyn Field	Independent Chairman of the Board	less than a year	Nessun dato	Nessun dato

0.2yrs

Durata media

37.5yo

Età media

Consiglio di amministrazione esperto: Il consiglio di amministrazione di ISPC non è considerato esperto (durata media del mandato 0.2 anni), il che suggerisce un nuovo consiglio.

iSpecimen Gestione

Gestione criteri di controllo 0/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Less than half of directors are independent

Ispecimen Inc. Announces Executive Changes

iSpecimen Inc. Receives A Letter of Resignation from Christopher Ianelli to Resign as A Director

Less than half of directors are independent

iSpecimen Appoints Eric Langlois as Chief Revenue Officer

Secretary & Director exercised options to buy US$108k worth of stock.

Recent updates

New major risk - Shareholder dilution

Third quarter 2024 earnings released: US$2.10 loss per share (vs US$4.66 loss in 3Q 2023)

iSpecimen Inc. has completed a Follow-on Equity Offering in the amount of $4.999845 million.

iSpecimen Inc. has completed a Follow-on Equity Offering in the amount of $5 million.

iSpecimen Inc. has filed a Follow-on Equity Offering in the amount of $5 million.

Less than half of directors are independent

iSpecimen Inc. announced that it has received $1 million in funding from 1396974 B.C. Ltd

New major risk - Revenue and earnings growth

iSpecimen Inc. (NASDAQ:ISPC) Might Not Be As Mispriced As It Looks After Plunging 32%

US$3.00: That's What Analysts Think iSpecimen Inc. (NASDAQ:ISPC) Is Worth After Its Latest Results

Second quarter 2024 earnings: EPS exceeds analyst expectations

iSpecimen Inc. to Report Q2, 2024 Results on Aug 06, 2024

First quarter 2024 earnings: EPS and revenues miss analyst expectations

iSpecimen Inc. to Report Q1, 2024 Results on May 07, 2024

New major risk - Share price stability

Nasdaq Grants an Additional 180 Calendar Day Period, or Until October 7, 2024 to iSpecimen to Regain Compliance with the Minimum Bid Price Requirement

New minor risk - Shareholder dilution

Consensus revenue estimates fall by 16%

Full year 2023 earnings: EPS and revenues miss analyst expectations

iSpecimen Inc. to Report Fiscal Year 2023 Results on Mar 13, 2024

iSpecimen Inc. has filed a Follow-on Equity Offering in the amount of $1.5 million.

Take Care Before Diving Into The Deep End On iSpecimen Inc. (NASDAQ:ISPC)

Ispecimen Inc. Announces Executive Changes

Consensus estimates of losses per share improve by 15%

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

New major risk - Share price stability

iSpecimen Inc. Provides Revenue Guidance for Third Quarter 2023

iSpecimen Inc. to Report Q3, 2023 Results on Nov 02, 2023

iSpecimen Inc. Receives a Deficiency Notice from the Nasdaq Stock Market

iSpecimen Inc. Launches Next-Day Quote Service for Medical Researchers and Biospecimen Providers

Ispecimen Expands Provider Network to Enhance Support for Women's Health Research

iSpecimen Enhances Proprietary Marketplace Platform to Streamline Biospecimen Matchmaking for Researchers and Providers

Consensus revenue estimates fall by 23%

Downgrade: Here's How This Analyst Sees iSpecimen Inc. (NASDAQ:ISPC) Performing In The Near Term

New minor risk - Shareholder dilution

Price target decreased by 38% to US$5.00

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

iSpecimen Inc. to Report Q2, 2023 Results on Aug 02, 2023

iSpecimen Inc. Receives A Letter of Resignation from Christopher Ianelli to Resign as A Director

Less than half of directors are independent

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Investors Still Aren't Entirely Convinced By iSpecimen Inc.'s (NASDAQ:ISPC) Revenues Despite 33% Price Jump

Full year 2022 earnings: EPS and revenues exceed analyst expectations

iSpecimen Appoints Eric Langlois as Chief Revenue Officer

Secretary & Director exercised options to buy US$108k worth of stock.

iSpecimen Inc. Appoints Tracy Curley as Chief Executive Officer

Now 21% undervalued after recent price drop

iSpecimen Inc. Appoints Joseph J. Basile to Board of Directors

Less than half of directors are independent

iSpecimen Inc. Announces Board Changes

Price target decreased to US$7.63

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased to US$7.63

iSpecimen Inc. Launches New Open Feasibilities Dashboard on the Ispecimen Marketplace Platform to Enhance Biospecimen Fulfillment for Global Partner Network

iSpecimen Inc. to Report Q3, 2022 Results on Nov 08, 2022

iSpecimen Inc. Announces Executive Changes

iSpecimen names finance chief Tracy Curley as interim CEO

Consensus revenue estimates fall by 13%

iSpecimen Inc. (NASDAQ:ISPC) Analysts Just Slashed This Year's Estimates

Price target decreased to US$9.83

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Price target decreased to US$10.83

iSpecimen GAAP EPS of -$0.30 misses by $0.02, revenue of $2.3M misses by $0.55M

iSpecimen Inc. to Report Q2, 2022 Results on Aug 04, 2022

First quarter 2022 earnings: EPS and revenues miss analyst expectations

iSpecimen Inc. to Report Q1, 2022 Results on May 10, 2022

iSpecimen Inc. Unveils Enhanced iSpecimen Marketplace Platform to Help Scientists More Efficiently

iSpecimen Inc., Annual General Meeting, May 25, 2022

iSpecimen Inc.'s (NASDAQ:ISPC) Intrinsic Value Is Potentially 69% Above Its Share Price